Dr. Theodore DeWeese has been named permanent CEO of Johns Hopkins Medicine and dean of the Johns Hopkins University School of Medicine.
DeWeese, a radiation oncologist, has served in both roles on an interim basis since July 2022. He succeeded Dr. Paul Rothman, who retired after a decade at the helm.
Related: How Johns Hopkins looks to boost safety through tech
As CEO of Johns Hopkins Medicine, DeWeese oversees more than 40,000 employees across six hospitals, 39 outpatient sites and multiple surgery centers in three states and the District of Columbia, in addition to international hospital management, consulting and clinical education services. Since taking the interim roles, DeWeese has overseen multiple projects, including a new life sciences corridor for biomedical research and a 12-story research tower for health sciences.
DeWeese joined Johns Hopkins in 1991 as a radiation oncology resident and joined the faculty in 1995. In 2003, he became the founding director of the medical school's Department of Radiation Oncology. He was named vice dean of clinical affairs in 2018.
